Back to Journals » Therapeutics and Clinical Risk Management » Volume 15
Review
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Risk of immune-related adverse events associated with ipilimumab-plus-nivolumab and nivolumab therapy in cancer patients
Total article views | HTML views | PDF downloads | Totals | ||
---|---|---|---|---|---|
14,973 | Dovepress* | 8,623+ | 2,159 | 10,782 | |
PubMed Central* | 6,350 | 667 | 7,017 | ||
Totals | 14,973 | 2,826 | 17,799 | ||
*Since 31 January 2019 |
Total mentioned | Delicious | Others | |||
---|---|---|---|---|---|
2 | 1 | 0 | 0 | 0 | 1 |
View citations on PubMed Central and Google Scholar